#Japan #Tokyo #Proton Therapy #FUNDINNO #BeDot Medical

Innovative Cancer Treatment Advances

A significant milestone has been achieved by BeDot Medical, a groundbreaking venture in cancer treatment technology. Funded through the service FUNDINNO PLUS+, the company has successfully raised approximately 1 billion yen in capital. This funding initiative is a remarkable step toward revolutionizing proton beam cancer treatment with a compact, high-performance device designed for enhanced accessibility.

Established as a spin-off from the National Institute of Radiological Sciences, BeDot Medical specializes in developing, manufacturing, and selling proton therapy devices. Typically, proton therapy equipment has been cumbersome, often requiring extensive facilities due to its size and weight. However, thanks to BeDot Medical's innovative technology, the new device measures a third in height and weighs a tenth of the original models, significantly reducing costs associated with construction. This breakthrough enables hospitals, particularly in urban environments where space and resources are limited, to easily incorporate proton therapy centers.

In an exciting announcement, BeDot Medical, with a commitment to broaden patient options, is relaunching its investment opportunity for select investors through FUNDINNO PLUS+ on August 12, 2025. The company encourages potential investors who meet specific criteria to join in its vision for more accessible cancer treatment solutions. This reopening reflects strong investor interest, demonstrating confidence in BeDot Medical's transformative impact on healthcare.

Collaboration with Local Healthcare Institutions

As part of its commitment to enhancing cancer treatment accessibility, BeDot Medical reached an agreement with the Edogawa Hospital Group, leading to the establishment of a Proton Therapy Center at Edogawa Medicare Hospital in Tokyo. This center marks a significant first in the capital, eliminating the need for local patients to travel to other prefectures for proton therapy, thus vastly improving treatment availability for those affected by cancer.

Executive Insights

Takuji Furukawa, CEO of BeDot Medical, expressed his gratitude for the overwhelming support received from participating investors through FUNDINNO PLUS+. He emphasized that the funding goes beyond mere financial support—it creates opportunities for connections with individuals committed to shaping the future of cancer treatment. The forthcoming round of investment solicitation is seen as a chance for a broader audience to engage with BeDot Medical’s pioneering efforts in healthcare.

What is FUNDINNO PLUS+?

FUNDINNO PLUS+ is an innovative platform that allows startups to secure substantial funding while offering investors an opportunity to support promising, up-and-coming companies approaching their IPOs. By registering as a special investor, participants can gain access to investment opportunities in burgeoning enterprises like BeDot Medical, which holds potential for balanced risk and return.

This initiative not only empowers startups to thrive within Japan's venture capital ecosystem but also bridges the funding gap for entrepreneurs and investors alike.

Conclusion

As the landscape of cancer treatment evolves, BeDot Medical's advancements create a pathway toward making proton therapy a viable option for all individuals wishing to explore this innovative treatment. The combination of cutting-edge technology, strategic partnerships, and community investment is poised to change the face of cancer care. As the reopening of investment for March 2025 approaches, the opportunity to be part of this groundbreaking venture awaits qualified investors eager to support the future of healthcare in Japan.

For more information on BeDot Medical and their ambitious projects, please visit their official site.